521

ALT, FIBROSCAN VCTE, AND FIBROSCAN CAP AS PREDICTIVE MARKERS OF RESMETIROM BIOPSY RESPONSE

Date
May 19, 2024
Explore related products in the following collection:

There are no comments to view

Tracks

Related Products

Thumbnail for A BLOOD-BASED BIOMARKER PANEL FOR NON-INVASIVE DIAGNOSIS OF METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS
A BLOOD-BASED BIOMARKER PANEL FOR NON-INVASIVE DIAGNOSIS OF METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS
BACKGROUND: Metabolic dysfunction-associated steatotic liver disease (MASLD) and its more severe form metabolic dysfunction-associated steatohepatitis (MASH) are highly prevalent worldwide. However, current non-invasive diagnostic approaches for MASLD and MASH are suboptimal…